RxDoctor Payments Data

Suhas Neerukonda, MD

Internal Medicine · St Augustine, FLNPI 1538145602

Payments from drug & device makers

$20,784in general payments, 2019–2025

Across 243 payments — averaging $85.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$17K
  • Novo Nordisk$1K
  • AstraZeneca$366
  • Amgen$184
  • Integra Lifesciences Corporation$157
  • Novartis$133
  • plus $2K from 45 others

What the payments were for

  • Food & beverage$3,98419%
  • Education$7,20035%
  • Other$9,60046%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,784 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$148,668
Medicare patients
343
Services billed
2,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$151,788
FarxigaDapagliflozin Propanediol89$88,437
OzempicSemaglutide29$39,351
XareltoRivaroxaban43$33,871
JardianceEmpagliflozin23$33,724
MounjaroTirzepatide22$29,545
MyrbetriqMirabegron24$29,233
JanuviaSitagliptin Phosphate38$26,708
Xigduo XrDapaglifloz Propaned/Metformin21$22,321
RybelsusSemaglutide16$20,041
Breo ElliptaFluticasone/Vilanterol28$18,380
JanumetSitagliptin Phos/Metformin Hcl13$9,399
LivaloPitavastatin Calcium12$8,069
EntrestoSacubitril/Valsartan12$7,302
ArexvyRsvpref3 Antigen/As01e/Pf22$6,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$366$88,43789 claims
Novo NordiskOzempic, Rybelsus$1,449$59,39245 claims
MerckJanuvia, Janumet$83$36,10751 claims
Johnson & JohnsonXarelto$16$33,87143 claims
Boehringer IngelheimJardiance$26$33,72423 claims
Lilly USA, LLCMounjaro$75$29,54522 claims
Astellas Pharma US IncMyrbetriq$83$29,23324 claims
GSKBreo Ellipta, Arexvy$55$25,31350 claims
Kowa Pharmaceuticals America, Inc.Livalo$46$8,06912 claims
NovartisEntresto$133$7,30212 claims
AbbVieSynthroid$61$1,55135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in St Augustine

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →